Day: March 7, 2022
FDA Approves Nivolumab Plus Chemo as Neoadjuvant Therapy for NSCLC Treatment
The FDA has approved nivolumab plus platinum-doublet chemotherapy for patients with non-small cell lung cancer in the neoadjuvant setting. Nivolumab is the [...]